NovoCure (NVCR) Shares Outstanding (Weighted Average) (2014 - 2026)
NovoCure recorded quarterly Shares Outstanding (Weighted Average) of $114.1 million in Q1 2026, up 2.4% quarter-over-quarter from $111.5 million in Q4 2025, and up 3.51% year-over-year from $110.3 million in Q1 2025.
NovoCure's Shares Outstanding (Weighted Average) history runs 13 years deep, the most recent figure standing at $114.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) rose 3.51% year-over-year to $114.1 million; the TTM figure through Mar 2026 stood at $114.1 million (up 3.51% YoY), while the FY2025 annual figure was $111.5 million, up 3.37% from the prior year.
- Shares Outstanding (Weighted Average) came in at $114.1 million for Q1 2026 at NovoCure, up from $111.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $114.1 million in Q1 2026 to a low of $104.2 million in Q1 2022.
- A 5-year average of $107.8 million and a median of $107.3 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- Across the five-year window, Shares Outstanding (Weighted Average) climbed 1.1% in 2022 and advanced 3.6% in 2025, its largest moves.
- NovoCure's Shares Outstanding (Weighted Average) stood at $104.7 million in 2022, then advanced by 1.65% to $106.4 million in 2023, then increased by 1.36% to $107.8 million in 2024, then advanced by 3.37% to $111.5 million in 2025, then rose by 2.4% to $114.1 million in 2026.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $114.1 million, $111.5 million, and $111.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.74 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 382.90 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.28 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.48 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 579.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 385.10 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 456.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 98.20 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 114.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 114.15 Mn |
| Dec 31, 2025 | 111.47 Mn |
| Sep 30, 2025 | 111.26 Mn |
| Jun 30, 2025 | 111.57 Mn |
| Mar 31, 2025 | 110.28 Mn |
| Dec 31, 2024 | 107.83 Mn |
| Sep 30, 2024 | 107.68 Mn |
| Jun 30, 2024 | 107.70 Mn |
| Mar 31, 2024 | 107.27 Mn |
| Dec 31, 2023 | 106.39 Mn |
| Sep 30, 2023 | 106.22 Mn |
| Jun 30, 2023 | 106.29 Mn |
| Mar 31, 2023 | 105.67 Mn |
| Dec 31, 2022 | 104.66 Mn |
| Sep 30, 2022 | 104.88 Mn |
| Jun 30, 2022 | 104.63 Mn |
| Mar 31, 2022 | 104.19 Mn |
| Dec 31, 2021 | 103.43 Mn |
| Sep 30, 2021 | 103.73 Mn |
| Jun 30, 2021 | 103.48 Mn |
| Mar 31, 2021 | 102.63 Mn |
| Dec 31, 2020 | 100.93 Mn |
| Sep 30, 2020 | 101.23 Mn |
| Jun 30, 2020 | 100.72 Mn |
| Mar 31, 2020 | 99.88 Mn |
| Dec 31, 2019 | 99.23 Mn |
| Sep 30, 2019 | 98.49 Mn |
| Jun 30, 2019 | 96.36 Mn |
| Mar 31, 2019 | 94.81 Mn |
| Dec 31, 2018 | 91.83 Mn |
| Sep 30, 2018 | 92.91 Mn |
| Jun 30, 2018 | 91.33 Mn |
| Mar 31, 2018 | 89.99 Mn |
| Dec 31, 2017 | 88.55 Mn |
| Sep 30, 2017 | 89.13 Mn |
| Jun 30, 2017 | 88.22 Mn |
| Mar 31, 2017 | 87.45 Mn |
| Dec 31, 2016 | 86.76 Mn |
| Sep 30, 2016 | 85.77 Mn |
| Jun 30, 2016 | 85.27 Mn |
| Mar 31, 2016 | 84.40 Mn |
| Dec 31, 2015 | 30.40 Mn |
| Sep 30, 2015 | 12.43 Mn |
| Jun 30, 2015 | 12.43 Mn |
| Mar 31, 2015 | 13.14 Mn |
| Dec 31, 2014 | 12.49 Mn |
| Sep 30, 2014 | 12.38 Mn |